[1] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for
36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):
209-249.
[2] Zhou M, Wang H, Zeng X. Mortality, morbidity, and risk factors
in China and its provinces, 1990-2017: a systematic analysis
for the Global Burden of Disease Study 2017[J]. Lancet, 2019,
396(10204): 1145-1158.
[3] Kulik L, El-Serag HB. Epidemiology and Management of
Hepatocellular Carcinoma[J]. Gastroenterology, 2019, 156(2):
477-491. e1.
[4] 中华人民共和国国家卫生健康委员会. 原发性肝癌诊疗
指南(2022年版)[J]. 肿瘤防治研究, 2022, 49(3): 251-276.
[National Health Commission of the People’s Republic of China.
Standardization for diagnosis and treatment of primary hepatic
carcinoma[J]. Zhong Liu Fang Zhi Yan Jiu, 2022, 49(3): 251-276.]
[5] Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma[J].
Lancet, 2012, 379(9822): 1245-1255.
[6] Roberts LR, Sirlin CB, Zaiem F, et al. Imaging for the diagnosis
of hepatocellular carcinoma: A systematic review and metaanalysis[
J]. Hepatology, 2018, 67(1): 401-421.
[7] Farwell MD, Pryma DA, Mankoff DA. PET/CT Imaging in
Cancer: Current Applications and Future Directions[J]. Cancer,
2014, 120(22): 3433-3445.
[8] Tsurusaki M, Okada M, Kuroda H, et al. Clinical application
of 18F-fluorodeoxyglucose positron emission tomography for
assessment and evaluation after therapy for malignant hepatic
tumor[J]. J Gastroenterol, 2014, 49(1): 46-56.
[9] Gündo?an C, Ergül N, ?ak?r MS, et al. 68Ga-PSMA PET/
CT Versus 18F-FDG PET/CT for Imaging of Hepatocellular
Carcinoma[J]. Mol Imaging Radionucl Ther, 2021, 30(2): 79-85.
[10] Abouzied MM, Alhinti N, AlMuhaideb A, et al. Extrahepatic
metastases from hepatocellular carcinoma: multimodality image
evaluation[J]. Nucl Med Commun, 2021, 42(6): 583-591.
[11] Ayuso C, Rimola J, Vilana R, et al. Diagnosis and staging of
hepatocellular carcinoma (HCC): Current guidelines[J]. Eur J
Radiol, 2018, 101: 72-81.
[12] Kwee SA, Wong LL, Hernandez BY, et al. Chronic Liver
Disease and the Detection of Hepatocellular Carcinoma by
18F fluorocholine PET/CT[J]. Diagnostics (Basel), 2015, 5(2):
189-199.
[13] Castilla-Lièvre MA, Franco D, Gervais P, et al. Diagnostic value
of combining 11C-choline and 18F-FDG PET/CT in hepatocellular
carcinoma[J]. Eur J Nucl Med Mol Imaging, 2016, 43(5):
852-859.
[14] ?elebi F, Yaghouti K, Cindil E, et al. The Role of 18F-FDG PET/
MRI in the Assessment of Primary Intrahepatic Neoplasms[J].
Acad Radiol, 2021, 28(2): 189-198.
[15] Sharma B, Martin A, Zerizer I. Positron Emission Tomography-
Computed Tomography in Liver Imaging[J]. Semin Ultrasound
CT MR, 2013, 34(1): 66-80.
[16] Lee JE, Jang JY, Jeong SW, et al. Diagnostic value for
extrahepatic metastases of hepatocellular carcinoma in positron
emission tomography/computed tomography scan[J]. World J
Gastroenterol, 2012, 18(23): 2979-2987.
[17] Kim YK, Lee KW, Cho SY, et al. Usefulness 18F-FDG positron
emission tomography/computed tomography for detecting
recurrence of hepatocellular carcinoma in posttransplant
patients[J]. Liver Transpl, 2010, 16(6): 767-772.
[18] Refaat R, Basha MAA, Hassan MS, et al. Efficacy of contrastenhanced
FDG PET/CT in patients awaiting liver transplantation
with rising alpha-fetoprotein after bridge therapy of hepatocellular
carcinoma[J]. Eur Radiol, 2018, 28(12): 5356-5367.
[19] Filippi L, Schillaci O, Bagni O. Recent advances in PET probes
for hepatocellular carcinoma characterization[J]. Expert Rev Med
Devices, 2019, 16(5): 341-350.
[20] Yamamoto Y, Nishiyama Y, Kameyama R, et al. Detection of
hepatocellular carcinoma using 11C-choline PET: comparison
with 18F-FDG PET[J]. J Nucl Med, 2008, 49(8): 1245-1248.
[21] Chotipanich C, Kunawudhi A, Promteangtrong C, et al.
Diagnosis of hepatocellular carcinoma using C-11 choline PET/
CT: Comparison with F-18 FDG, contrast-enhanced MRI and
MDCT[J]. Asian Pac J Cancer Prev, 2016, 17(7): 3569-3573.
[22] Park JW, Kim JH, Kim SK, et al. A Prospective Evaluation of
18F-FDG and 11C-Acetate PET/CT for Detection of Primary and
Metastatic Hepatocellular Carcinoma[J]. J Nucl Med, 2008,
49(12): 1912-1921.
[23] Signore G, Nicod-Lalonde M, Prior JO, et al. Detection rate of
radiolabelled choline PET or PET/CT in hepatocellular carcinoma:
an updated systematic review and meta-analysis[J]. Clin Transl
Imaging, 2019, 7(2): 237-253.
[24] Cheung TT, Ho CL, Lo CM, et al. 11C-Acetate and 18F-FDG
PET/CT for Clinical Staging and Selection of Patients with
Hepatocellular Carcinoma for Liver Transplantation on the Basis
of Milan Criteria: Surgeon's Perspective[J]. J Nucl Med, 2013,
54(2): 192-200.
[25] Donadon M, Lopci E, Galvanin J, et al. Prognostic Value of
Metabolic Imaging Data of 11C-choline PET/CT in Patients
Undergoing Hepatectomy for Hepatocellular Carcinoma[J].
Cancers (Basel), 2021, 13(3): 472.
[26] Lanza E, Donadon M, Felisaz P, et al. Refining the management
of patients with hepatocellular carcinoma integrating C-11-choline
PET/CT scan into the multidisciplinary team discussion[J]. Nucl
Med Commun, 2017, 38(10): 826-836.
[27] Dondi F, Albano D, Cerudelli E, et al. Radiolabelled PSMA PET/
CT or PET/MRI in hepatocellular carcinoma (HCC): a systematic
review[J]. Clin Transl Imaging, 2020, 8(2): 461-467.
[28] Shi X, Xing H, Yang X, et al. Fibroblast imaging of hepatic
carcinoma with 68Ga-FAPI-04 PET/CT: a pilot study in patients
with suspected hepatic nodules[J]. Eur J Nucl Med Mol Imaging,
2021, 48(1): 196-203.
[29] Kunikowska J, Cie?lak B, Gierej B, et al. 68Ga-Prostate-Specific
Membrane Antigen PET/CT: a novel method for imaging patients
with hepatocellular carcinoma[J]. Eur J Nucl Med Mol Imaging,
2021, 48(3): 883-892.
[30] Tolkach Y, Goltz D, Kremer A, et al. Prostate-specific membrane
antigen expression in hepatocellular carcinoma: potential use for
prognosis and diagnostic imaging[J]. Oncotarget, 2019, 10(41):
4149-4160.
[31] Mikhail K, Charles L, Dov H, et al. Ga-68-Labeled Prostate-
Specific Membrane Antigen Is a Novel PET/CT Tracer for
Imaging of Hepatocellular Carcinoma: A Prospective Pilot
Study[J]. J Nucl Med, 2019, 60(2): 185-191.
[32] Kunikowska J, Cie?lak B, Gierej B, et al. 68Ga-Prostate-Specific
Membrane Antigen PET/CT: a novel method for imaging patients
with hepatocellular carcinoma[J]. Eur J Nucl Med Mol Imaging,
2021, 48(3): 883-892.
[33] Kuyumcu S, Has-Simsek D, Iliaz R, et al. Evidence of Prostate-
Specific Membrane Antigen Expression in Hepatocellular
Carcinoma Using 68Ga-PSMA PET/CT[J]. Clin Nucl Med, 2019, 44(9): 702-706.
[34] Kratochwil C, Flechsig P, Lindner T, et al. 68Ga-FAPI PET/CT:
Tracer Uptake in 28 Different Kinds of Cancer[J]. J Nucl Med,
2019, 60(6): 801-805.
[35] Wang H, Zhu WW, Ren SH, et al. 68Ga-FAPI-04 Versus 18F-FDG
PET/CT in the Detection of Hepatocellular Carcinoma[J]. Front
Oncol, 2021, 11: 693640.
[36] Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for
hepatocellular carcinoma: Expansion of the tumor size limits
does not adversely impact survival[J]. Hepatology, 2001, 33(6):
1394-1403.
[37] Chen J, Xu X, Wu J, et al. The stratifying value of Hangzhou
criteria in liver transplantation for hepatocellular carcinoma[J].
PLoS One, 2014, 9(3): e93128.
[38] Jia F, Yang GS, Fu ZR, et al. Liver transplantation outcomes in
1,078 hepatocellular carcinoma patients: a multi-center experience
in Shanghai, China[J]. J Cancer Res Clin Oncol, 2009, 135(10):
1403-1412.
[39] Welker MW, Bechstein WO, Zeuzem S, et al. Recurrent
hepatocellular carcinoma after liver transplantation-an emerging
clinical challenge[J]. Transpl Int, 2012, 26(2): 109-118.
[40] Takada Y, Kaido T, Shirabe K, et al. Significance of preoperative
fluorodeoxyglucose-positron emission tomography in prediction
of tumor recurrence after liver transplantation for hepatocellular
carcinoma patients: a Japanese multicenter study[J]. J
Hepatobiliary Pancreat Sci, 2017, 24(1): 49-57.
[41] Kornberg A, Schernhammer M, Friess H. 18F-FDG-PET for
Assessing Biological Viability and Prognosis in Liver Transplant
Patients with Hepatocellular Carcinoma[J]. J Clin Transl Hepatol,
2017, 5(3): 224-234.
[42] Kornberg A, Küpper B, Tannapfel A, et al. Patients with non-
[18F]fludeoxyglucose-avid advanced hepatocellular carcinoma on
clinical staging may achieve long-term recurrence-free survival
after liver transplantation[J]. Liver Transpl, 2012, 18(1): 53-61.
[43] Kornberg A, Witt U, Schernhammer M, et al. Combining
18F-FDG positron emission tomography with Up-to-seven criteria
for selecting suitable liver transplant patients with advanced
hepatocellular carcinoma[J]. Sci Rep, 2017, 7(1): 14176.
[44] Kornberg A, Freesmeyer M, B?rthel E, et al. 18F-FDG-uptake of
hepatocellular carcinoma on PET predicts microvascular tumor
invasion in liver transplant patients[J]. Am J Transplant, 2009,
9(3): 592-600.
[45] Hsu C, Chen C, Wang C, et al. Combination of FDG-PET and
UCSF Criteria for Predicting HCC Recurrence After Living
Donor Liver Transplantation[J]. Transplantation, 2016, 100(9):
1925-1932.
[46] Lee SD, Kim SH, Kim SK, et al. Clinical Impact of
18F-Fluorodeoxyglucose Positron Emission Tomography/
Computed Tomography in Living Donor Liver Transplantation for
Advanced Hepatocellular Carcinoma[J]. Transplantation, 2015,
99(10): 2142-2149.
[47] Lee SD, Kim SH, Kim YK, et al. 18F-FDG-PET/CT predicts
early tumor recurrence in living donor liver transplantation for
hepatocellular carcinoma[J]. Transpl Int, 2013, 26(1): 50-60.
[48] Lim C, Salloum C, Chalaye J, et al. 18F-FDG PET/CT predicts
microvascular invasion and early recurrence after liver resection
for hepatocellular carcinoma: A prospective observational
study[J]. HPB (Oxford), 2019, 21(6): 739-747.
[49] Sun DW, An L, Wei F, et al. Prognostic significance of parameters
from pretreatment 18F-FDG PET in hepatocellular carcinoma: a
meta-analysis[J]. Abdom Radiol (NY), 2016, 41(1): 33-41.
[50] So n g MJ , Ba e SH, Yo o IR, e t a l . Pr e d i c t i v e v a l u e
of 18F- f luorodeoxyglucos e PET/CT for t r ans a r t e r i a l
chemolipiodolization of hepatocellular carcinoma[J]. World J
Gastroenterol, 2012, 18(25): 3215-3222.
[51] Song MJ, Bae SH, Lee SW, et al. 18F-fluorodeoxyglucose PET/CT
predicts tumour progression after transarterial chemoembolization
in hepatocellular carcinoma[J]. Eur J Nucl Med Mol Imaging,
2013, 40(6): 865-873.
|
